THE EFFECT OF HEPATOPROTECTIVE THERAPY ON THE COURSE OF CHRONIC DIFFUSE LIVER DISEASES

Abstract

Relevance of the topic: chronic diffuse liver diseases are characterized by an
increase in the level of hepatic fibrosis and stable development with the eventual
formation of liver cirrhosis. Currently, it is recognized that hepatic fibrosis is the main
negative prognostic factor, therefore it is very important in practical medicine to
determine and explain the degree of its severity. However, many issues related to the
diagnosis and treatment of chronic diffuse liver disease remain poorly studied. Most
often, liver damage occurs secretly without any clinical manifestations or is "masked"
under other diseases, but even a latent course of these chronic diseases can cause
cirrhosis of the liver. Early diagnosis of chronic diffuse liver disease and correct
therapeutic tactics are able to prevent some irreversible consequences, therefore, to
determine the severity of fibrosis in patients with chronic diffuse liver diseases at
different stages of the disease, which makes it possible to determine the course of the
disease, the reverse side of the detected.